These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 36128766

  • 1. Treatment of acquired transthyretin amyloidosis in domino liver transplantation.
    Tsamis KI, Mytilinaios D, Heneghan M, Gillmore JD, Gilbertson JA, Giannopoulos S, Sarmas I, Konitsiotis S.
    Clin Transplant; 2023 Jan; 37(1):e14822. PubMed ID: 36128766
    [Abstract] [Full Text] [Related]

  • 2. [de novo hATTR amyloidosis after domino transplantation of a donor's liver: a case report for the use of Patisiran].
    Schmidt M, Yilmaz A, Bietenbeck M, Schilling M, Röcken C, Schmidt HH.
    Z Gastroenterol; 2022 Nov; 60(11):1659-1664. PubMed ID: 35533685
    [Abstract] [Full Text] [Related]

  • 3. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M, Yabe I, Tsuda M, Sakakibara M, Shimamura T, Sasaki H.
    Intern Med; 2017 Dec 01; 56(23):3231-3235. PubMed ID: 28943540
    [Abstract] [Full Text] [Related]

  • 4. Recipient aging accelerates acquired transthyretin amyloidosis after domino liver transplantation.
    Misumi Y, Narita Y, Oshima T, Ueda M, Yamashita T, Tasaki M, Obayashi K, Isono K, Inomata Y, Ando Y.
    Liver Transpl; 2016 May 01; 22(5):656-64. PubMed ID: 26600212
    [Abstract] [Full Text] [Related]

  • 5. Carpal Tunnel Syndrome Due to Iatrogenic Amyloidosis After Domino Liver Transplantation From Hereditary Transthyretin Amyloidosis: A Case Report.
    Ohya Y, Tasaki M, Hayashida S, Katayama N, Tsuchida T, Kuriwaki K, Ueda M, Inomata Y.
    Transplant Proc; 2021 May 01; 53(4):1313-1316. PubMed ID: 33836864
    [Abstract] [Full Text] [Related]

  • 6. Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation.
    Muchtar E, Grogan M, Dasari S, Kurtin PJ, Gertz MA.
    J Neurol Sci; 2017 Aug 15; 379():192-197. PubMed ID: 28716239
    [Abstract] [Full Text] [Related]

  • 7. Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.
    Dixit N, Castano A, Farr MJ, Traub R, Lentzsch S, Brown RS, Maurer MS, Brannagan TH.
    J Clin Neuromuscul Dis; 2016 Mar 15; 17(3):142-5. PubMed ID: 26905915
    [Abstract] [Full Text] [Related]

  • 8. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation.
    Lladó L, Baliellas C, Casasnovas C, Ferrer I, Fabregat J, Ramos E, Castellote J, Torras J, Xiol X, Rafecas A.
    Liver Transpl; 2010 Dec 15; 16(12):1386-92. PubMed ID: 21117248
    [Abstract] [Full Text] [Related]

  • 9. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.
    J Clin Pharmacol; 2020 Jan 15; 60(1):37-49. PubMed ID: 31322739
    [Abstract] [Full Text] [Related]

  • 10. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH, Wixner J, Planté-Bordeneuve V, Muñoz-Beamud F, Lladó L, Gillmore JD, Mazzeo A, Li X, Arum S, Jay PY, Adams D, Patisiran Post-LT Study Group.
    Am J Transplant; 2022 Jun 15; 22(6):1646-1657. PubMed ID: 35213769
    [Abstract] [Full Text] [Related]

  • 11. Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study.
    Vollmar J, Schmid JC, Hoppe-Lotichius M, Barreiros AP, Azizi M, Emrich T, Geber C, Schad A, Weyer V, Otto G, Heise M, Mittler J, Birklein F, Lang H, Galle PR, Zimmermann T.
    Transpl Int; 2018 Nov 15; 31(11):1207-1215. PubMed ID: 30091268
    [Abstract] [Full Text] [Related]

  • 12. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O.
    Circulation; 2019 Jan 22; 139(4):431-443. PubMed ID: 30586695
    [Abstract] [Full Text] [Related]

  • 13. Symptomatic Val122del mutated hereditary transthyretin amyloidosis: Need for early diagnosis and prioritization for heart and liver transplantation.
    Schettini AV, Llado L, Heimbach JK, Costello JG, Tranäng M, Van Caenegem O, Daly RC, Van den Bergh P, Casanovas C, Fabregat J, Poterucha JJ, Foguenne M, Ericzon BG, Lerut J.
    Hepatobiliary Pancreat Dis Int; 2021 Aug 22; 20(4):323-329. PubMed ID: 34116942
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
    Badri P, Habtemariam B, Melch M, Clausen VA, Arum S, Li X, Jay PY, Vest J, Robbie GJ.
    Clin Pharmacokinet; 2023 Oct 22; 62(10):1509-1522. PubMed ID: 37639169
    [Abstract] [Full Text] [Related]

  • 15. Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation.
    Barreiros AP, Geber C, Birklein F, Galle PR, Otto G.
    Liver Transpl; 2010 Jan 22; 16(1):109. PubMed ID: 20035516
    [No Abstract] [Full Text] [Related]

  • 16. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS, Brandão PRP, Faber I, Titze-de-Almeida R.
    Mol Diagn Ther; 2020 Feb 22; 24(1):49-59. PubMed ID: 31701435
    [Abstract] [Full Text] [Related]

  • 17. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL, Claeys KG, Delstanche S, Van Parys V, Baets J, Tilleux S, Remiche G.
    Acta Neurol Belg; 2023 Jun 22; 123(3):1029-1037. PubMed ID: 36829087
    [Abstract] [Full Text] [Related]

  • 18. Progressive Multiple Mononeuropathy in a Patient With Familial Transthyretin Amyloidosis After Liver Transplantation.
    Seibert K, Wlodarski R, Sarswat N, Appelbaum D, Issa NP, Soliven B, Rezania K.
    J Clin Neuromuscul Dis; 2022 Mar 01; 23(3):143-147. PubMed ID: 35188911
    [Abstract] [Full Text] [Related]

  • 19. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD.
    JAMA Cardiol; 2019 May 01; 4(5):466-472. PubMed ID: 30878017
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.